Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Seladelpar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD known ✓ | Q03181 | 20/20 | 1.00 |
| ▸ | PPARA | Q07869 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Seladelpar SCHEMBL392331 | 1.00 | PPARD (1.00) | PPARDPPARA | |
| Seladelpar SCHEMBL390098 | 1.00 | PPARD (1.00) | PPARDPPARA | |
| Seladelpar SCHEMBL29373526 | 1.00 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL3701620 | 0.94 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL16726808 | 0.94 | PPARD (0.88) | PPARDPPARA | |
| SCHEMBL3695586 | 0.93 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL377933 | 0.93 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL377934 | 0.93 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL3700528 | 0.93 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL3694382 | 0.92 | PPARD (1.00) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370467-A1 | USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | WASHINGTON UNIVERSITY | 2022-11-24 | — | — | US | claimed |
| US-11406611-B2 | Treatment of intrahepatic cholestatic diseases | CYMABAY THERAPEUTICS, INC. (US) | 2022-08-09 | — | — | US | claimed |
| US-20220023306-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | RENEO PHARMACEUTICALS, INC. | 2022-01-27 | — | — | US | claimed |
| EP-3927718-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | Reneo Pharmaceuticals, Inc. (US) | 2021-12-29 | — | — | EP | claimed |
| EP-3920903-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | Reneo Pharmaceuticals, Inc. (US) | 2021-12-15 | — | — | EP | claimed |
| CN-113747891-A | Use of PPAR delta agonists in the treatment of Fatty Acid Oxidation Disorders (FAOD) | 雷内奥制药公司 | 2021-12-03 | — | — | CN | claimed |
| CN-113710683-A | Use of PPAR-delta agonists in the treatment of mitochondrial myopathy | 雷内奥制药公司 | 2021-11-26 | — | — | CN | claimed |
| WO-2021055725-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | RENEO PHARMACEUTICALS, INC. (US) | 2021-03-25 | — | — | WO | claimed |
| US-20210023031-A1 | Treatment of intrahepatic cholestatic diseases | CYMABAY THERAPEUTICS, INC. (US) | 2021-01-28 | — | — | US | claimed |
| US-10828273-B2 | Treatment of intrahepatic cholestatic diseases | CYMABAY THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | claimed |
| EP-1937065-B1 | NOVEL LYSINE SALTS OF 4-((PHENOXYALKYL) THIO)-PHENOXYACETIC ACID DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-28 | — | — | EP | claimed |
| US-8669288-B2 | Lysine salts of 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-03-11 | — | — | US | claimed |
| US-20130331453-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-12 | — | — | US | claimed |
| EP-2100877-B1 | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-25 | — | — | EP | claimed |
| US-20110105616-A1 | NOVEL LYSINE SALTS OF 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACID DERIVATIVES | CYMABAY THERAPEUTICS, INC. | 2011-05-05 | — | — | US | claimed |
| US-7709682-B2 | Lysine salts of 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-05-04 | — | — | US | claimed |
| EP-1937065-A2 | NOVEL LYSINE SALTS OF 4-((PHENOXYALKYL) THIO)-PHENOXYACETIC ACID DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | claimed |
| US-7301050-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICAL N.V. (BE) | 2007-11-27 | — | — | US | claimed |
| WO-2007033231-A2 | NOVEL LYSINE SALTS OF 4-((PHENOXYALKYL) THIO)-PHENOXYACETIC ACID DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-22 | — | — | WO | claimed |
| US-20070060649-A1 | NOVEL LYSINE SALTS OF 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACID DERIVATIVES | CYMABAY THERAPEUTICS, INC. | 2007-03-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023031-A1 | Treatment of intrahepatic cholestatic diseases | SLC10A1, SLC10A2, NR1H4 | PPARD 1511/4885PPARA 1726/4885 |
| US-11406611-B2 | Treatment of intrahepatic cholestatic diseases | SLC10A1, SLC10A2, NR1H4 | PPARD 1511/4885PPARA 1726/4885 |
| US-20220370467-A1 | USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | PPARG, PPARA, PPARD | PPARD 3/4885PPARA 2/4885 |
| US-20070060649-A1 | NOVEL LYSINE SALTS OF 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACID DERIVATIVES | PPARA, PPARD, PPARG | PPARD 2/4885PPARA 1/4885 |
| US-20110105616-A1 | NOVEL LYSINE SALTS OF 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACID DERIVATIVES | PPARA, PPARD, PPARG | PPARD 2/4885PPARA 1/4885 |
| US-20130331453-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885 |
| US-10828273-B2 | Treatment of intrahepatic cholestatic diseases | SLC10A1, SLC10A2, NR1H4 | PPARD 1511/4885PPARA 1726/4885 |
| US-20220023306-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | PPARD, ACOX1, CPT1A | PPARD 1/4885PPARA 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.